Skip to main content
Clinical Trials/NCT01454271
NCT01454271
Withdrawn
Phase 1

Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate

Laboratoire Ceraver-Osteal1 site in 1 countryOctober 18, 2011

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hip Arthroplasty Replacement
Sponsor
Laboratoire Ceraver-Osteal
Locations
1
Primary Endpoint
Femoral component osseous-integration
Status
Withdrawn
Last Updated
7 years ago

Overview

Brief Summary

The risk of infection after primary Total Hip Arthroplasties (THA)is generally estimated to be less than 1% but remains a severe and costly complication, source of morbidity and even mortality. The "biofilm" forms very early after the bacterial contamination of the prosthesis and poses a number of clinical challenges due to his resistance to immune defence mechanisms and antibiotics. Preventive strategies are needed. The poly sodium styrene sulfonate (pNaSS) is a bioactive polymer. In vitro and in vivo studies showed that poly sodium styrene sulfonate grafted on titane surfaces reduce significantly the bacterial adhesion. They also proved his biocompatibility and osseous-integration.

Registry
clinicaltrials.gov
Start Date
October 18, 2011
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Laboratoire Ceraver-Osteal
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age less than 75 years old
  • Aetiologies for THA : primary osteoarthritis, inflammatory diseases,Osteonecrosis

Exclusion Criteria

  • Previous infectious hip arthritis
  • Previous surgeries on the operated hip
  • Revision of THA

Outcomes

Primary Outcomes

Femoral component osseous-integration

Time Frame: 1 year after surgery

Scoring system of Engh

Secondary Outcomes

  • Infection rate(1 year after surgery)
  • Quality of Life(One, three, six and twelve months after surgery)

Study Sites (1)

Loading locations...

Similar Trials